Stay updated on Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial
Sign up to get notified when there's something new on the Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial page.

Latest updates to the Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference13%
- Check20 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, signaling a new release/version without altering core content or critical data.SummaryDifference0.3%
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe page now shows Revision: v3.0.2 instead of v3.0.1, and the Back to Top element was removed; overall content remains essentially the same.SummaryDifference0.8%
- Check42 days agoChange DetectedThe recruitment status for Actinium Pharmaceuticals has been updated to 'Unknown status', indicating a significant change in the information provided about the clinical trial. Additionally, the version of the document has been revised from v3.0.0 to v3.0.1.SummaryDifference3%
- Check49 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, while removing specific location details and previous status verifications.SummaryDifference12%
- Check63 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12, indicating a revision in the content.SummaryDifference0.3%
Stay in the know with updates to Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial page.